Totals
- Total revenue
- $10,968,237
- Total expenses
- $14,851,654
- Contributions and grants received
- $7,968,991
- Grants paid
- $10,238,599
- Program service revenue
- $0
- Investment income
- $343,112
- Other revenue
- $2,656,134
- Total assets, end of year
- $11,857,815
- Total liabilities, end of year
- $2,822,688
- Net assets or fund balances, end of year
- $9,035,127
- Program services expenses (Part IX)
- $11,714,338
- Management and general expenses
- $1,688,385
- Fundraising expenses
- $1,448,931
- Program service expenses (Part III)
- $11,714,338
Program services were 78.9% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1c · Fundraising events
$5,455,260
-
1f · All other contributions, gifts and grants
$2,513,731
-
1g · Noncash contributions included above
$1,341,246
-
3 · Investment income
total $343,112 · excluded $343,112
-
8a · Fundraising events: gross income
$10,551,539
-
8a · Fundraising events: contributions included on line 1c
$5,455,260
-
8b · Fundraising events: direct expenses
$7,895,405
-
8c · Net income from fundraising events
total $2,656,134 · excluded $2,656,134
Functional expenses
Part IX, the statement of functional expenses.
-
1 · Grants to domestic organizations and governments
total $10,238,599 · program services $10,238,599
-
5 · Compensation of officers, directors and key employees
total $823,076 · program services $411,538 · management and general $205,769 · fundraising $205,769
-
7 · Other salaries and wages
total $1,703,341 · program services $643,557 · management and general $411,879 · fundraising $647,905
-
9 · Other employee benefits
total $199,643 · program services $43,199 · management and general $119,815 · fundraising $36,629
-
10 · Payroll taxes
total $185,996 · program services $72,811 · management and general $40,374 · fundraising $72,811
-
11b · Fees: legal
total $36,797 · management and general $36,797
-
11c · Fees: accounting
total $53,874 · management and general $53,874
-
11g · Fees: other
total $792,339 · program services $190,375 · management and general $253,094 · fundraising $348,870
-
12 · Advertising and promotion
total $69,355 · management and general $21,165 · fundraising $48,190
-
13 · Office expenses
total $35,802 · management and general $35,108 · fundraising $694
-
14 · Information technology
total $161,966 · program services $42,391 · management and general $119,575
-
16 · Occupancy
total $319,124 · program services $39,514 · management and general $211,017 · fundraising $68,593
-
17 · Travel
total $36,455 · management and general $36,455
-
19 · Conferences, conventions and meetings
total $52,322 · program services $11,175 · management and general $41,147
-
22 · Depreciation, depletion and amortization
total $18,291 · management and general $18,291
-
23 · Insurance
total $52,546 · management and general $52,546
-
24a · Other expenses: DUES AND SUBSCRIPTION
total $31,983 · program services $0 · management and general $30,983 · fundraising $1,000
-
24b · Other expenses: FOOD AND BEVERAGE
total $21,038 · program services $21,038 · management and general $0 · fundraising $0
-
24c · Other expenses: PARTICIPANT DIRECT EXPE
total $12,006 · program services $141 · management and general $0 · fundraising $11,865
-
24d · Other expenses: EQUIPMENT AND RENTAL
total $4,158 · program services $0 · management and general $0 · fundraising $4,158
-
24e · All other expenses
total $2,943 · management and general $496 · fundraising $2,447
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $1,238,683 · end of year $1,296,640
-
2 · Savings and temporary cash investments
beginning of year $8,297,334 · end of year $6,045,173
-
3 · Pledges and grants receivable
beginning of year $6,172,121 · end of year $3,734,254
-
9 · Prepaid expenses and deferred charges
beginning of year $338,409 · end of year $154,066
-
14 · Intangible assets
beginning of year $33,806 · end of year $15,515
-
15 · Other assets
beginning of year $360,530 · end of year $612,167
-
17 · Accounts payable and accrued expenses
beginning of year $270,843 · end of year $181,232
-
18 · Grants payable
beginning of year $1,012,360 · end of year $1,237,579
-
19 · Deferred revenue
beginning of year $1,875,372 · end of year $786,006
-
25 · Other liabilities
beginning of year $363,764 · end of year $617,871
-
27 · Net assets without donor restrictions
beginning of year $6,746,423 · end of year $5,374,341
-
28 · Net assets with donor restrictions
beginning of year $6,172,121 · end of year $3,660,786
Mission and programs · 2025
Mission
CUREBOUND'S MISSION IS TO ACCELERATE CANCER RESEARCH AND SAVE LIVES. WE RAISE AND INVEST STRATEGIC FUNDING FOR INNOVATIVE ADULT AND PEDIATRIC CANCER RESEARCH WITH ONE VISION: CURES IN OUR LIFETIME.
Activities or mission (Part I)
MOBILIZE SAN DIEGO TO ACCELERATE CURES FOR CANCER IN OUR LIFETIME.
-
CUREBOUND IS A COMMUNITY-POWERED CANCER RESEARCH ACCELERATOR WITH A UNIQUE FUNDING MODEL BUILT ON A CORE BELIEF THAT THE BEST IDEAS HAPPEN WHEN THE RIGHT PEOPLE WORK TOGETHER. WE UNITE TOP SCIENTISTS, PASSIONATE ADVOCATES, ENTREPRENEURS AND INVESTORS TO ADVANCE CANCER RESEARCH THAT HAS THE GREATEST OPPORTUNITY TO IMPROVE DETECTION, TREATMENT, AND SURVIVORSHIP. ALL CUREBOUND GRANTS DEMAND SCIENTIFIC COLLABORATION ACROSS INSTITUTIONS TO DRIVE RESULTS FOR PATIENTS WHO NEED IT NOW. THROUGH RIGOROUS REVIEW AND TRANSPARENCY, WE DIRECT EVERY INVESTMENT DOLLAR TOWARDS MEANINGFUL IMPACT. REPRESENTATIVE RESEARCH PARTNER INSTITUTIONS INCLUDE (BUT NOT LIMITED TO): UC SAN DIEGO MOORES CANCER CENTER, THE SALK INSTITUTE, SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, RADY CHILDREN'S HOSPITAL, SCRIPPS RESEARCH, AND LA JOLLA INSTITUTE OF IMMUNOLOGY.HEADQUARTERED IN SAN DIEGO, ONE OF THE NATION'S PREMIER HUBS FOR CANCER RESEARCH AND LIFE-SCIENCE INNOVATION, CUREBOUND CATALYZES COMPLEMENTARY STRENGTHS ACROSS BIOLOGY, TECHNOLOGY, DATA SCIENCE, AND CLINICAL NETWORKS TO ACCELERATE THE TRANSLATION OF DISCOVERY INTO CLINICAL IMPACT. CUREBOUND ALLOCATES AND ADMINISTERS RESEARCH FUNDING THROUGH FIVE GRANT MECHANISMS SPANNING DISCOVERY THROUGH CLINICAL TRANSLATION: DISCOVERY, TARGETED, CATALYST, EQUITY, CURE PRIZE. EACH OF THESE GRANT TYPES ALIGNS TO CUREBOUND'S OVERARCHING AND RESEARCH ROADMAP WITH CLEARLY DEFINED TIMELINES AND MEASURABLE MILESTONES THAT ARE TRACKED TO ACCELERATE PROGRESS.
Expenses $11,714,338 · Grants $10,238,599
As filed on the 2025 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
Donald B Kearns MD MmmDONALD B KEARNS MD MMM
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
John Hood PhDJOHN HOOD PHD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Rob SinghROB SINGH
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Haeyoung Tang PhDHAEYOUNG TANG PHD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Fe WhitworthFE WHITWORTH
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Dan RyanDAN RYAN
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Court Turner JDCOURT TURNER JD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Mark CaffertyMARK CAFFERTY
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Catriona Jamieson MD PhDCATRIONA JAMIESON MD PHD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Rich Heyman PhDRICH HEYMAN PHD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Magda Marquet PhDMAGDA MARQUET PHD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Julie Tafel KlausJULIE TAFEL KLAUS
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Cheryl Am Anderson PhD MPH MsCHERYL AM ANDERSON PHD MPH MS
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Chris TresseCHRIS TRESSE
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Larry BlochLARRY BLOCH
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Aaron DavisAARON DAVIS
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Bill KomanBILL KOMAN
CHAIRPERSON
- Total calculated
- $0
- Hours/week
- 1
-
Karen HooperKAREN HOOPER
CHIEF OPERATING OFFICER
- Total calculated
- $325,985
- From this org
- $306,167
- From related orgs
- $0
- Other
- $19,818
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $220,500
- Bonus
- $85,667
- Other
- $0
- Deferred
- $11,043
- Nontaxable benefits
- $8,775
- Filer's total
- $325,985
-
Robin ToftROBIN TOFT
SECRETARY
- Total calculated
- $0
- Hours/week
- 1
-
Don AnkenyDON ANKENY
TREASURER
- Total calculated
- $0
- Hours/week
- 1
-
Rick ValenciaRICK VALENCIA
VICE-CHAIR
- Total calculated
- $0
- Hours/week
- 1
-
Anne MarbargerANNE MARBARGER
CHIEF EXECUTIVE OFFICER
- Total calculated
- $497,091
- From this org
- $476,750
- From related orgs
- $0
- Other
- $20,341
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $323,750
- Bonus
- $153,000
- Other
- $0
- Deferred
- $13,470
- Nontaxable benefits
- $6,871
- Filer's total
- $497,091
-
Megan AmbroseMEGAN AMBROSE
CHIEF OF STAFF
- Total calculated
- $149,791
- From this org
- $142,448
- From related orgs
- $0
- Other
- $7,343
- Hours/week
- 40
-
Heather Dean-PresnallHEATHER DEAN-PRESNALL
SR. DIRECTOR, STEWARDSHIP
- Total calculated
- $163,962
- From this org
- $149,198
- From related orgs
- $0
- Other
- $14,764
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $130,729
- Bonus
- $18,469
- Other
- $0
- Deferred
- $5,989
- Nontaxable benefits
- $8,775
- Filer's total
- $163,962
-
Judith PolhaJUDITH POLHA
DIRECTOR, RESEARCH & IMPACT
- Total calculated
- $142,639
- From this org
- $137,153
- From related orgs
- $0
- Other
- $5,486
- Hours/week
- 40
-
Amy MyersAMY MYERS
SR. DIRECTOR, PHILANTHROPY
- Total calculated
- $149,239
- From this org
- $146,937
- From related orgs
- $0
- Other
- $2,302
- Hours/week
- 40
-
Erik Hans GordonERIK HANS GORDON
DIRECTOR, MARKETING
- Total calculated
- $142,301
- From this org
- $134,195
- From related orgs
- $0
- Other
- $8,106
- Hours/week
- 40
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 3 · Written employment contract
- 3 · Approval by the board or compensation committee
- 7 · Other non-fixed payments
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 8 · Paid under the initial-contract exception
The filer's explanations (Part III)
- PART I, LINE 7
- ALL EMPLOYEES RECEIVED PERFORMANCE BONUSES.
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
-
SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
-
$1,529,548
SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
-
SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
-
$537,267
SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
-
LA JOLLA INSTITUTE FOR IMMUNOLOGY
$385,027
SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
-
SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
-
BEKEN BIO INC
$250,000
SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
-
RESOLUTE SCIENCE INC
$250,000
SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
-
ILLUDENT INC
$250,000
SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
-
UNIVERSITY OF ARIZONA
$100,000
SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
The 10 largest by cash amount. The API serves every itemized grant.
Provenance
- Return type
- form_990
- Tax year
- 2025
- Filed
- 16 July 2026
- IRS schema version
- 2025v4.2
- Source object
- 202642059349300634
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.